J Korean Med Assoc.  2007 Apr;50(4):369-374. 10.5124/jkma.2007.50.4.369.

Drug Therapy for Alzheimer's Disease

• Suh GH

• KMID: 2184855
• DOI: http://doi.org/10.5124/jkma.2007.50.4.369

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. AD afflicts 0.3 to 0.5 million people in Korea, and the number is projected to increase to 2 million by the year of 2050. This article provides a brief overview of the most popular drug therapies in the treatment of AD including cholinesterase inhibitors (AchEIs) (donepezil, galantamine, rivastigmine), NMDA receptor antagonist (memantine), acetyl-l-carnitine, antioxidant vitamins, and Ginko biloba. Based on a review of relevant papers in the literature, this article presents pharmacological and clinical safety profiles of these agents and prescribing tips as well as a final summary on the effectiveness, safety, and alerts for clinicians. AchEIs as well as memantine will continue to play an important role in the treatment armamentarium for AD, even though newer strategies are being explored. There is not enough evidence supporting the continuous use of other drugs such as acetyl-l-carnitine, antioxidant vitamins, and Ginko biloba for the treatment of AD.

Keyword

Alzheimer; drug therapy; cholinesterase inhibitor; memantine; Ginko biloba

MeSH Terms

Acetylcarnitine
Aged
Alzheimer Disease*
Cholinesterase Inhibitors
Dementia
Drug Therapy*
Galantamine
Ginkgo biloba
Humans
Korea
Memantine
N-Methylaspartate
Vitamins
Acetylcarnitine
Cholinesterase Inhibitors
Galantamine
Memantine
N-Methylaspartate
Vitamins

Reference

1. Suh GH. Dementia in Korea: Trend and Projection. Journal of Korean Geriatric Psychiatry. 2002. 6:28–35.

2. Herbert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995. 273:1354–1359.

3. Suh GH, Kee BS, Jung HY, Yoo SH. Drug therapy in geriatrics. 2006. 1st ed. Seoul: Jungang Moonhwa Co;36–65.

4. Sano M, Ernesto C, Thomas RG, Klanber MR, Schafer K, Grundman M, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997. 336:1216–1222.